Skip to main content

Silence Therapeutics PLC (SLN)

NASDAQ: SLN · IEX Real-Time Price · USD
21.73 -0.97 (-4.27%)
Oct 21, 2021 1:35 PM EDT - Market closed
Market Cap707.75M
Revenue (ttm)5.48M
Net Income (ttm)-32.55M
Shares Out29.93M
EPS (ttm)-2.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume69
Open-
Previous Close22.70
Day's Range21.73 - 21.73
52-Week Range15.00 - 35.00
Beta1.22
AnalystsStrong Buy
Price Target2,342.78 (+10,681.3%)
Est. Earnings Daten/a

About SLN

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-as...

IndustryBiotechnology
CEODavid Solomon
Employees65
Stock ExchangeNASDAQ
Ticker SymbolSLN
Full Company Profile

Financial Performance

In 2020, SLN's revenue was $5.48 million, an increase of 2,145.49% compared to the previous year's $244,000. Losses were -$32.55 million, 66.2% more than in 2019.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SLN stock is "Strong Buy." The 12-month stock price forecast is 2,342.78, which is an increase of 10,681.32% from the latest price.

Price Target
$2,342.78
(10,681.32% upside)
Analyst Consensus: Strong Buy

News

Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its P...

Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market

6 days ago - GlobeNewsWire

Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence's mRNAi GOLD...

Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence's mRNAi GOLD™ Platform

6 days ago - GlobeNewsWire

Silence Therapeutics to Host R&D Day on October 21, 2021

Silence Therapeutics to Host R&D Day on October 21, 2021

2 weeks ago - GlobeNewsWire

Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference

Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference

3 weeks ago - GlobeNewsWire

Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management ...

Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development

1 month ago - GlobeNewsWire

Silence Therapeutics to Participate in September Investor Conferences

Silence Therapeutics to Participate in September Investor Conferences

1 month ago - GlobeNewsWire

Silence Therapeutics Reports Half-Year 2021 Results

Silence Therapeutics Reports Half-Year 2021 Results

2 months ago - GlobeNewsWire

Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA ...

Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration

4 months ago - GlobeNewsWire

Silence Therapeutics receives US$40mln tranche from AstraZeneca tie-up

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it has received the final US$40mln from a US$80mln cash and equity investment from AstraZeneca, adding that it expects to be working on up to five tar...

Other symbols:AZN
4 months ago - Proactive Investors

Silence Therapeutics' siRNA Candidate Reduces Plasma Iron Levels, Early-Stage Study Shows

Silence Therapeutics plc (NASDAQ: SLN) has announced topline data from GEMINI Phase 1 study evaluating SLN124 for iron-loading anemia conditions, thalassemia, and myelodysplastic syndrome (MDS). SLN124 ...

5 months ago - Benzinga

Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers

Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers

5 months ago - GlobeNewsWire

Silence Therapeutics shares positive data from phase I study of its lead asset

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) has reported positive safety data from a phase I trial of its lead asset. SLN124, which is being developed to treat iron-loading anaemia conditions such as...

5 months ago - Proactive Investors

Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference

Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference

5 months ago - GlobeNewsWire

Silence Therapeutics says phase I trial of lead asset is now underway

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) has begun treating the first patient in the phase I study of its lead asset. SLN124 is being developed for the treatment of types of anaemia, the blood dis...

5 months ago - Proactive Investors

Silence Therapeutics receives further US$2mln under Mallinckrodt deal

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said had received a further US$2mln from commercial partner Mallinckrodt under a deal potentially worth up to US$2bn in milestones and royalties. In 2019, ...

Other symbols:MNKKQ
5 months ago - Proactive Investors

Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Ther...

Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease

6 months ago - GlobeNewsWire

Silence Therapeutics assess the use of RNAi in heart disease

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said its medics and scientist has contributed to a peer-reviewed paper that explores the “promising potential” RNA interference (RNAi) therapies for treati...

6 months ago - Proactive Investors

Silence Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Silence Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

6 months ago - GlobeNewsWire

Silence Therapeutics Reports Full-year 2020 Results

Silence Therapeutics Reports Full-year 2020 Results Advancing clinical programmes; On-track for three phase 1 data readouts in 2021

6 months ago - GlobeNewsWire

Silence Therapeutics continues to progress high-value partnerships

What does Silence do? The name of Silence Therapeutics PLC (LON: SLN, NASDAQ: SLN) provides a hint as to what it does.

6 months ago - Proactive Investors

Silence Therapeutics ready to make a bigger noise in 2021

Silence Therapeutics PLC (LON:SLN) is cashed up and ready to pick up the pace in 2021 after a transformational 2020, it told investors. Cash and cash equivalents at the end of 2020, the company had cash...

6 months ago - Proactive Investors

Silence Therapeutics receives US$2mln as Mallinckrodt collaboration moves onto third drug target

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it will receive US$2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt. The two are focuse...

Other symbols:MNKKQ
7 months ago - Proactive Investors

Silence Therapeutics begins phase I trial of Lipoprotein (a) drug

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it has begun dosing patients with SLN360, a putative treatment for elevated Lipoprotein (a), ‘bad' cholesterol associated with increased risk of heart...

8 months ago - Proactive Investors

Silence Therapeutics fundraise underlines strength of support

What does Silence do? The name of Silence Therapeutics PLC (LON: SLN, NASDAQ: SLN) provides a hint as to what it does.

8 months ago - Proactive Investors

Proactive news headlines: Iconic Labs, Silence Therapeutics, Chaarat Gold, Tiziana Life Sciences.

Iconic Labs PLC (LON:ICON), a multidivisional new media and technology business, announced that it has appointed Sarah Dees as its chief executive officer and an executive director with immediate effect...

Other symbols:TLSA
8 months ago - Proactive Investors